Drug development by therapeutic area
How much development is happening in each disease area, how often drugs in that area have historically been approved, and which experimental drugs we track there.
Cardiovascular
Cardiovascular drug development, from LDL cholesterol and lipoprotein(a) to heart failure and hypertension: active industry trials, historical approval odds, and the experimental drugs we track.
474 active industry trials · 168 in Phase 3 · historical approval from Phase 1: 4.8% (Cardiovascular) · 7 tracked drugs
Metabolic
Obesity, type 2 diabetes, and metabolic liver disease drug development: active industry trials, historical approval odds, and the incretin and amylin drugs reshaping the field.
657 active industry trials · 244 in Phase 3 · historical approval from Phase 1: 15.5% (Metabolic) · 3 tracked drugs
Oncology
Cancer drug development, from lung and breast cancer to pancreatic, colorectal, and endometrial cancer: active industry trials, historical approval odds, and the experimental and newly approved drugs we track.
2,624 active industry trials · 598 in Phase 3 · historical approval from Phase 1: 5.3% (Oncology) · 5 tracked drugs
Approval odds from BIO, Informa Pharma Intelligence, QLS Advisors (2021). The all-indication average is 7.9% from Phase 1.